SETBP1 overexpression associates with FAB M0 AML subtype. (A) SETBP1 expression (Affymetrix, median-centered intensity) in FAB M0 AMLs compared with other FAB subtypes in the 3 independent data sets TCGA (i), Wouters (ii), and Valk (iii), from the Oncomine database (median ± interquartile range; Student t test). (B) SETBP1 expression (RNA-seq) in 151 leukemia samples (TCGA) by FAB subtype, confirming higher SETBP1 expression in M0. Mean ± standard deviation. ***P < .0005, ****P < .0005, 1-way ANOVA. (C) SETBP1 and HOXA9 expression (RNA-seq) in different FAB AML subtypes from the TCGA cohort. M0 samples predominantly clustered at the SETBP1^high/HOXA9^high quadrant with many, but not all, harboring RUNX1 mutations. Reflecting their enrichment (the high number of M0 leukemias), SETBP1^high/HOXA9^high AMLs gene expression patterns show enrichment in an HSC gene signature. NES, normalized enrichment score.